Drugs / 20% D-glucose (aq)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT06558422 Background | Jan 2027 → Dec 2028 expected | hyperinsulinism, metabolic dysfunction-associated steatotic liver disease, obesity disorder, prediabetes syndrome | Columbia University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06126354 Background | Jul 2024 → Nov 2025 | NAFLD1, prediabetes syndrome | Columbia University | Withdrawn | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 20% D-glucose (aq) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06126354 ↗ |